Does APUS pay a dividend and is it safe?

Apimeds Pharmaceuticals US Inc. (APUS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / APUS / dividends

AZTR (33) TRAW (31) XBIO (32) CANF (25) ⌘ Pro Terminal →

Apimeds Pharmaceuticals US Inc. (APUS) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.89 -3.99% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.86

Apimeds Pharmaceuticals US Inc. (APUS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $4.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APUS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.89 (-3.99% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APUS ranks #553 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APUS compare to AZTR and TRAW in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.2%. By comparison, AZTR (Azitra Inc) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and TRAW (Traws Pharma Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $4.5M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APUS?

▼

Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $33.4M in revenue (+834.2% YoY), -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.86 (-0.91%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APUS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY APUS SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.62-26.2% Next Q

Q2 (-2Q)

Grade D$3.41-10.6% Next Q

Q3 (-1Q)

Grade D$3.05-5.2% Next Q

Current

Grade D-$2.89-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APUS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APUS currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($3.03) forces dealer call-delta covering toward $62.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APUS)

✓Walkthrough of APUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.63%🛡️ HOLDING TREND SUPPORT

2026-11-03O $3.21H $3.21L $2.89C $2.89VOL 21.5K

RES: $12.46SUP: $-1.30SMA50: $3.63SMA200: $10.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APUS Butterfly Map → + Track APUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APUS)

Health Care Rank #553 of 1016 ⚔️ AZTR vs APUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APUS vs. AZTR, TRAW, XBIO, CANF)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apimeds Pharmaceuticals US Inc. (APUS) ranks #553 by composite RQD confidence (37/100, grade D-) and #952 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, APUS leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. APUS currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APUS ACTIVE Apimeds Pharmaceuticals US Inc.	D-	37/100	—	—	-6.2%	-3.99%	$4.6M	Benchmark Subject
AZTR Azitra Inc	E	33/100	—	—	-35.0%	+8.72%	$4.7M	/aztr-vs-apus →
TRAW Traws Pharma Inc.	E	31/100	—	—	-35.0%	+1.45%	$4.5M	/traw-vs-apus →
XBIO Xenetic Biosciences Inc.	E	32/100	—	—	-30.3%	+0.49%	$4.8M	/xbio-vs-apus →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	25/100	—	—	-35.0%	+0.62%	$4.9M	/canf-vs-apus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894525

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported GAAP revenue of $33.4M (+834.2% vs. FY2024 revenue of $3.6M , and +1493.8% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-1124.6% YoY). On the balance sheet, APUS closed FY2025 with $164.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.4M	-$6.0M	-$8.9M	-$9.0M	$164.2M	—
FY2024 (FY)	2024-12-31	$3.6M	-$1.4M	-$733.5K	-$733.5K	$13.1K	—
FY2023 (FY)	2023-12-31	$2.1M	-$777.7K	-$627.8K	-$627.8K	—	—

3. APUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does APUS compare to AZTR and TRAW in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for APUS?

Where is APUS trading relative to its 50-day, 200-day, and 52-week technical levels?

APUS last traded at $2.89 (-3.99% on volume of 38,452 shares), positioning the stock -20.39% below its 50-day simple moving average ($3.63) and -73.14% below its 200-day simple moving average ($10.76). Across its 52-week range of $1.51 to $59.70, APUS sits at the 2.4% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.53 to $3.25).

Direct Sub-Reports: APUS RQD Cockpit APUS 12M Forecast APUS Earnings & Move APUS Dividends & DRIP APUS Insiders & 13F APUS Whale Options APUS Profit Sankey APUS News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

APUS — Apimeds Pharmaceuticals US Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:53:22Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

APUS scores 37 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -6.2% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to support valuation on a cash-earnings basis.
Whale 13F Flow: 3 / 20. Covers institutional accumulation and options positioning. This is the weakest pillar and suggests limited evidence of sophisticated-holder conviction in the source data.
Insider Conviction: 5 / 20. Covers SEC Form 4 and Congressional PTR cluster flow. A low score here means the source does not show meaningful insider buying conviction.
Macro Regime Fit: 11 / 20. Reflects beta of 1.0 and sector sensitivity. The stock moves in line with the market on this measure, offering no defensive cushion.
Forensic Balance Sheet: 10 / 20. Cites Altman Z-Score of 2.5, Piotroski F-Score of 1/9, and Debt/Equity of 0.5. The weak Piotroski reading is the key concern for an investor assessing financial health.

Upside drivers, as suggested by the rating's framework, would require improvement in cash generation and institutional or insider participation. The valuation tradeoff is that the market cap of $5.0M and share price of $3.21 sit against negative operating and net income in the reported periods, leaving little earnings-based valuation support in the source data. Investors should weigh the explicit "Sell" classification against any short-term price momentum visible in the news wire.

2. Business Model, Unit Margins & SEC Financial Trajectory

Apimeds Pharmaceuticals US Inc. Is listed on the NYSE and classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.0B on a rounded basis, which conflicts with the $5.0M figure in market data. Products, customers, and revenue model are —

Reported revenue is — in each period and operating and net losses widened from FY 2023 to FY 2025, with FY 2025 operating loss at -$11.9M. Gross, operating, and net margins are each listed as 0% in market data. ROIC is -6.2%. The Roarable RQD rating cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 1/9, with Debt/Equity of 0.5. Cash of $1.6M at FY 2025 is small relative to the -$9.0M free cash flow reported for the same year.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum traders. With Fundamental Cash Engine at 8/20 (ROIC -6.2%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.51 – $59.70 52-week range.
🐻 Primary Bear Case: With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity to fund operations without new capital. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —

Key Question #1: What specific product or pipeline drives the FY 2025 operating loss of -$11.9M, and what is the commercial timeline?
Key Question #2: What is the cash runway given $1.6M in cash against -$9.0M of FY 2025 free cash flow, and how is the gap financed?
Key Question #3: Why is the reported debt listed as N/A when Debt/Equity is cited at 0.5?

APUS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Apimeds Pharmaceuticals US Inc. (APUS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to APUS Debate Forum (3) ↓

🟢 CATALYST Benzinga • 20h ago

Why Is Apimeds Pharmaceuticals Stock Gaining Monday?

Benzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 23h ago

Why Did Apimeds (NYSEAMERICAN:APUS) Jump 55.3% After 42.5%?

kalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

APUS Stock Whipsaws As Traders Target Extreme Volatility

Timothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Apimeds Pharmaceuticals US (NYSEAM:APUS) - Stock Analysis

Simply Wall St report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Tuesday's Intraday Session - Apimeds Pharmaceuticals (AMEX:APUS), Option

Benzinga report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

APUS Stock Whipsaws As Traders Zero In On Volatility And Cash Burn

StocksToTrade report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

APUS Stock Whipsaws After Huge Run, Drawing Day Traders

Timothy Sykes report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Why Is Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) Up 8.29% Pre-Market on Tuesday? The Catalyst, the Fundamentals and What Comes Next

kalkine.ca report covering Apimeds Pharmaceuticals US Inc. (APUS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

APUS Bull vs. Bear Conversation Board — What's Your Call at $2.89?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON APUS 🐻 33% BEARISH CONVICTION

BR BreakoutHunter Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.67 (+21.9%)

📌 Pinned Debate

The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum t

Picked up a starter position in APUS in my $100K Virtual Cash book at $3.01. The stock rose 4.56% on 50,074 shares of volume, with news flow describing a sharp recent move that could attract short-term momentum traders.. Trading inside a $1.51–$59.70 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — APUS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $2.56 (-15.0%)

Spot @ $3.01

With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity t

Fading this rally in APUS at $3.01. With -$9.0M of FY 2025 free cash flow against $1.6M of cash, and a Piotroski F-Score of 1/9, the balance sheet shows limited capacity to fund operations without new capital.. With a beta of 1.0 and the stock sitting at $3.01 (52-wk range $1.51–$59.70), the easy multiple expansion is already priced in.